发明授权
- 专利标题： Identification marker responsive to interferon therapy for renal cell cancer
- 专利标题（中）： 用于肾细胞癌的干扰素治疗的鉴定标记物
-
申请号： US11666056申请日： 2005-10-24
-
公开(公告)号： US07838229B2公开(公告)日： 2010-11-23
- 发明人: Toyokazu Seki , Takayuki Shiratsuchi , Osamu Ogawa , Seiji Naito , Taiji Tsukamoto , Hiroshi Toma , Yoshihiko Hirao , Susumu Kagawa , Yoshiaki Nose , Tsuyoshi Nakamura
- 申请人： Toyokazu Seki , Takayuki Shiratsuchi , Osamu Ogawa , Seiji Naito , Taiji Tsukamoto , Hiroshi Toma , Yoshihiko Hirao , Susumu Kagawa , Yoshiaki Nose , Tsuyoshi Nakamura
- 申请人地址： JP Tokyo
- 专利权人： Otsuka Pharmaceutical Co., Ltd.
- 当前专利权人： Otsuka Pharmaceutical Co., Ltd.
- 当前专利权人地址： JP Tokyo
- 代理机构： Sughrue Mion, PLLC
- 优先权： JP2004-314160 20041028
- 国际申请： PCT/JP2005/019491 WO 20051024
- 国际公布： WO2006/046505 WO 20060504
- 主分类号： C07H21/04
- IPC分类号： C07H21/04 ; C12Q1/68
摘要：
The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator.
公开/授权文献
信息查询
